Join

or

Existing user? Login

Telaprevir improves hepatitis C treatment outcomes

By News team

Investigational hepatitis C drug telaprevir, in combination with the standard treatment of peginterferon alfa and ribavirin, is associated with improved rates of sustained virological response among previously untreated patients.

A phase III study reported in the (2011;364:2405) confirms earlier studies and suggests the drug combination has the potential to shorten treatment duration. Currently, at least 48 weeks of treatment with peginterferon alfa and ribavirin is required for most patients and toxic effects may limit treatment.

Over 1,000 patients with hepatitis C were assigned to treatment with peginterferon alfa-2a and ribavirin either placebo or the protease inhibitor telaprevir (see Panel). Significantly more patients who received either 12 or eight weeks of telaprevir treatment had a sustained virological response — defined as undetectable viral RNA 24 weeks after the last study dose — compared with those in the placebo group (75 per cent and 69 per cent versus 44 per cent; P<0.001).

Most patients who were treated with telaprevir had no detectable viral RNA at weeks four and 12 and required only 24 weeks of total therapy.

However, the incidence of gastrointestinal disorders such as nausea and diarrhoea, pruritus, rash and anaemia was at least 10 per cent higher with telaprevir than with placebo.

The study found higher response rates and a small increase in reversible adverse events with 12 weeks of telaprevir treatment compared with 8 weeks.

Study method and results

The researchers randomised 1,088 patients to one of three treatment groups assigned to peginterferon alfa-2a and ribavirin : placebo, for twelve weeks; telaprevir, for twelve weeks; or telaprevir for eight weeks and then placebo for four weeks.

This was followed by treatment with peginterferon alfa-2a and ribavirin for a further 12 weeks (36 weeks for those in the placebo group, or if viral RNA was detectable at weeks 4 or 12 in the plasma of those treated with telaprevir).

Citation: Electronicjuice URI: 11079600

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Complete Guide to Medical Writing (The)

    Effectively communicate scientific and medical information with The Complete Guide to Medical Writing.

    £27.00
  • Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00
  • Introduction to Clinical Pharmaceutics (An)

    This unique textbook covers the role of basic pharmaceutics in clinical outcomes and in explaining the behaviour of medicines in the body.

    £27.00
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00
  • Popular Medicines

    An illustrated history of some of the most popular branded medicines. Includes colourful historical adverts and details of the medicine's formula and intended purpose.

    £22.00

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

тадалафил варденафил

таблетки kamagra

оксандролон цена